Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) Profit After Tax (2020 - 2025)

Journey Medical (DERM) has disclosed Profit After Tax for 6 consecutive years, with -$2.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Profit After Tax rose 3.14% year-over-year to -$2.3 million, compared with a TTM value of -$8.7 million through Sep 2025, up 52.75%, and an annual FY2024 reading of -$14.7 million, down 280.79% over the prior year.
  • Profit After Tax was -$2.3 million for Q3 2025 at Journey Medical, up from -$3.8 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $16.8 million in Q3 2023 and bottomed at -$21.8 million in Q4 2021.
  • Average Profit After Tax over 5 years is -$5.4 million, with a median of -$4.1 million recorded in 2025.
  • The sharpest move saw Profit After Tax crashed 36810.34% in 2021, then soared 266.56% in 2023.
  • Year by year, Profit After Tax stood at -$21.8 million in 2021, then skyrocketed by 51.07% to -$10.6 million in 2022, then soared by 79.86% to -$2.1 million in 2023, then soared by 170.98% to $1.5 million in 2024, then plummeted by 252.2% to -$2.3 million in 2025.
  • Business Quant data shows Profit After Tax for DERM at -$2.3 million in Q3 2025, -$3.8 million in Q2 2025, and -$4.1 million in Q1 2025.